Anaphylaxis

Food Allergy

Seasonal Allergy

Allergy

Biosimilars

Arrhythmia

Atherosclerotic Cardiovascular Disease

Dyslipidemia

Heart Failure

Hypertension

Stroke

Structural Heart Disease

Venous Thromboembolism

Cardiology

Acne

Atopic Dermatitis

Chronic Idiopathic Urticaria

Plaque Psoriasis

Rosacea

Vitiligo

Dermatology

Hormonal Disorders

Polycystic Ovary Syndrome

Thyroid Disorders

Type 1 Diabetes

Type 2 Diabetes

Endocrinology

FDA News

COVID-19

Influenza

Vaccination

Family Medicine

C Difficile Infection

Gastroesophageal Reflux Disease (GERD)

Inflammatory Bowel Disease

Irritable Bowel Syndrome

Peptic Ulcer

Ulcerative Colitis

Gastroenterology

Alzheimer Disease

Parkinson Disease

Geriatrics

Anemia

Sickle Cell

Hematology

Alpha-1 antitrypsin deficiency

Cholangitis

Hepatitis C

MASH / MASLD

Hepatology

Hospital Medicine

HIV/AIDS

Infectious Disease

Internal Medicine

Chronic Kidney Disease

IgA Nephropathy

Nephrology

Epilepsy

Migraine

Tardive Dyskinesia

Traumatic Brain Injury

Neurology

Obesity Management

Age-Related Macular Degeneration

Diabetic Macular Edema

Geographic Atrophy

Uveitis

Ophthalmology

Acute Pain

Chronic Pain

Multiple Sclerosis

Neuropathic Pain

Pain

Pediatrics

ADHD

Addiction

Bipolar Disorder

Major Depressive Disorder

PTSD

Schizophrenia

Psychiatry

Asthma

COPD

Lung Cancer

Pulmonary Fibrosis

Pulmonology

Amyloidosis

Huntington Disease

Lysosomal Storage Disorders

Vasculitis

Rare Disease Report®

Fibromyalgia

Gout

Lupus

Osteoarthritis

Osteoporosis

Psoriatic Arthritis

Rheumatoid Arthritis

Spondyloarthritis

Rheumatology

Insomnia

Obstructive Sleep Apnea

Sleep

Plastic surgery

Surgery

Women's Health

News

Media

Podcasts

Shows

State Of Sciences - Presentations

Videos

Webinars

Multimedia Series

CURE Connections®

Insights

Medcast Podcasts

Medcast Videos

News Network

Peer Exchange

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

Partners

CME/CE

Resources

Digital Supplements

Interactive Tools

Live Events

Press Release

Publications

Advisory Board

Subscribe

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Articles

The increase will largely be driven by population growth and aging.

Gout Prevalence to Increase by More Than 70% by 2050 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.

Race and Ethnicity, Socioeconomic Status Influence Lp(a) Testing Rates

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

This interview with Culton featured a discussion of key challenges faced when treating patients with blistering diseases such as pemphigus and bullous pemphigoid.

Updates on the Diagnosis of Blistering Diseases, with Donna Culton, MD, PhD

Chelsie Derman is an assistant editor for 

who covers psychiatry, sleep medicine, and geriatrics. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.

Migraine Patients Achieve Remission of Medication Overuse Headaches with Erenumab

HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Information

Privacy

Terms & Conditions

HCPLive - Clinical news for connected physicians

Facebook

Twitter

LinkedIn

Spotlight

The Respiratory Report

Biosimilars Spotlight

DME & nAMD On-Demand Presentation

Clinical

Arterial Disease

Diabetes

Geriatric Medicine

Video Series

Post Conference Perspectives

1rem

Authors

After a Q1 filled with historic regulatory decisions, seismic levels of movement in the therapeutic pipeline, and noteworthy anniversaries, it would be hard to imagine a single specialty could be capable of maintaining such a breakneck pace of advancement throughout an entire year. However, the field of cardiology made it clear that was exactly what they intended to do as the onslaught of clinically relevant data and approvals continued through the month of April.

In our cardiology month in review, we spotlight the key news and updates that defined April 2024 for cardiology. The recap includes a look at FDA decisions and the most popular content from our on-site coverage of the American College of Cardiology’s 2024 Annual Scientific Sessions, which were held from April 6-8 in Atlanta, GA.

FDA Approves Abbott's Novel Dissolvable Stent Therapy for Peripheral Artery Disease

On April 29, 2024, the US Food and Drug Administration Abbott’s Esprit BTK Everolimus Eluting Resorbable Scaffold System for treating blocked arteries below the knee in patients with peripheral artery disease (PAD). This device, made of dissolvable material similar to sutures, offers a novel approach to addressing chronic limb-threatening ischemia below the knee, filling a crucial gap in available treatments.

The approval, announced by Abbott, follows data from the pivotal LIFE-BTK trial, presented at the Transcatheter Cardiovascular Therapeutics Conference in October 2023. This approval marks a significant advancement in addressing PAD, a condition affecting over 20 million Americans and associated with severe complications, including an elevated risk of amputation.

FDA Approves TriClip TEER System for Tricuspid Regurgitation

The approval of Abbott’s novel dissolvable stent marked the second cardiovascular approval for Abbott during April. Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system received approval from the US Food and Drug Administration for treating tricuspid regurgitation, announced on April 2, 2024. This decision follows positive outcomes of the TRILUMINATE trial and an endorsement from the FDA's Circulatory System Devices Panel. TRILUMINATE, a prospective randomized trial published in the New England Journal of Medicine in May 2023, demonstrated the effectiveness of TriClip in improving patient outcomes compared to medical therapy alone.

Recapping Q1 2024 FDA Decisions in Cardiology, with Deepak Bhatt, MD, MPH, MBA

With an interest in learning more about the community’s reaction to these approvals and how they influence care, we sat down with opinion leader Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Heart and the Dr. Valentin Foster Professor of Cardiovascular Medicine, for his perspective.

American College of Cardiology 2024 Annual Scientific Session

After the calendars turn over and the new year begins, the cardiology community’s first flagship meeting of the year is always the American College of Cardiology (ACC) Annual Scientific Session. This year’s meeting, ACC.24, drew more than 17,000 attendees between the conference’s virtual and in-person formatting. As part of our cardiology month in review for April 2024, we are highlighting the most popular stories from our coverage of the ACC’s annual meeting.

Experts' Perspectives: Advancements in Cardiomyopathy at ACC.24

In recent years, advancements in the treatment of cardiomyopathies have captivated the cardiology community. However, experts and opinion leaders in cardiomyopathy are quick to remind others this progress was not overnight and comes as the result of tireless efforts by colleagues and their predecessors dating back decades. In this video, we aggregate responses from a trio of leading experts in cardiomyopathy on their perspectives on the rapid pace of advancements in the last half-decade.

Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes

In this video, we sit down with Safia Chatur, MD, to discuss the study that earned her the meeting’s coveted Young Investigator award. In the study, Chatur and team assessed the effects of sacubitril/valsartan from within the PARADIGM-HF across the spectrum of renal impairment based on the 2024 KDIGO guidelines, which were released in early March.

Results of the study indicated a positive treatment effect of sacubitril/valsartan was observed across risk classifications, with no significant variation observed for those considered low (HR, 0.66; 95% CI, 0.47 to 0.93), moderate (HR, 0.82; 95% CI, 0.58 to 1.16), or high or very high risk (HR, 0.96; 95% CI, 0.70 to 1.32; 

for interaction = .31). For the renal outcome, relative treatment effects were consistent across the low (HR, 0.76; 95% CI, 0.51 to 1.11) and moderate (HR, 0.53; 95% CI, 0.33 to 0.84) KDIGO risk categories, but this effect was not observed in those considered as high or very high risk (HR, 0.66; 95% CI, 0.40 to 1.07; 

ACC.24 Clinical Trials Recap, with Deepak Bhatt, MD, MPH, MBA

Ahead of ACC.24 we spoke with Bhatt to preview the trials from late-breaking sessions he was looking forward to most as part of the meeting. As part of our post-conference coverage, we caught up with Bhatt to see what he considered to be the most impactful clinical trials to be presented at ACC.24. Bhatt’s list included EMPACT-MI, REDUCE-AMI, ULTIMATE DAPT, DanGer Shock, and AEGIS-II.

Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial

EMPACT-MI was designed as an event-driven, double-blind, randomized, placebo-controlled trial and randomized 6522 patients in a 1:1 ratio to empagliflozin or placebo in addition to standard of care within 14 days of admission for an acute myocardial infarction. The primary outcome of interest for the EMPACT-MI trial was a composite of first hospitalization for heart failure and all-cause mortality assessed in a time-to-first-event analysis.

Results of the primary outcome analysis suggested a first heart failure hospitalization or death occurred among 9.1% (n=267) of the placebo arm and 8.2% (n=298) of the empagliflozin arms, with incidence rates of 6.6 and 5.5 events, respectively, per 100 patient-years (HR, 0.90; 95% CI, 0.76 to 1.06; 

= .21). Analysis of individual components of the primary outcome indicated a first hospitalization for heart failure occurred among 4.7% (n=153) of the placebo arm and 3.6% (n=118) of the empagliflozin arm (HR, 0.77; 95% CI, 0.60 to 0.98).

Don't Miss a Beat: EMPACT-MI at ACC.24, with Javed Butler, MD

HCPLive Don't Miss a Beat Recap of EMPACT-MI

A new content offering embedded into our conference coverage for 2024 is the HCPLive 5. A video recap of our top 5 interviews from coverage, the HCPLive 5 for ACC.24 captured perspective in the areas of lipidology, cardiomyopathy, heart failure, and cardiovascular prevention. Our HCPLive 5 features perspective from the following:

 on the SHASTA-2 trial and plozasiran in severe hypertriglyceridemia.

 on the IMPROVE-HCM trial and ninerafaxstat for nonobstructive hypertrophic cardiomyopathy.

The April 2024 cardiology month in review spotlights FDA news and top updates from the American College of Cardiology 2024 Scientific Session.

Cardiology Month in Review: April 2024

Daniel Tashnek, JD

Articles

Latest Updated Articles